Metrics as of 10/16/2026, 03:46 AM (Berlin time), refresh in progress.
Alkermes Stock
Alkermes plc
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- CEO
- Blair Jackson
- Employees
- 2,050
- Market cap
- $6.9 B
- IPO
- 16/07/1991
Alkermes plc is a biopharmaceutical company within the Healthcare sector that engages in the research, development, and commercialization of pharmaceutical products. The company aims to address unmet medical needs for patients in the United States, Ireland, and internationally. Its portfolio includes proprietary…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Alkermes stock: price history
1D
+2.8%
1W
+1.5%
1M
-10.5%
6M
+19.4%
YTD
+47.3%
1Y
+33.8%
2Y
+46.7%
5Y
+30.2%
10Y
-2.6%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~30% stronger price swings than usual
Alkermes stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 24/08/2026.
Ask the agents about Alkermes
Analyst assessment of Alkermes
PRICE TARGET LOW
US$50.00
CONSENSUS
US$58.29
MEDIAN
US$56.00
PRICE TARGET HIGH
US$65.00
0
STRONG BUY
16
BUY
10
HOLD
3
SELL
0
STRONG SELL
29
TOTAL · Buy
As of: 22/09/2026
Alkermes stock metrics
P/E
102.28
P/B
3.8
EV/EBITDA
36.58
RETURN ON EQUITY
0.0%
NET MARGIN
0.1%
DEBT/EQUITY
0.87
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.5%
FLOAT SHARES
155,191,092
AVG. DAILY VOLUME (30D)
2,292,335
Insider transactions (SEC)
Reed Joshua
Reed Joshua
Gaffin David Joseph
Gaffin David Joseph
Hopkinson Craig C.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Alkermes stock
What does Alkermes do?
Alkermes plc is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Ireland.
The CEO is Blair Jackson, the company employs around 2,050 people.
The IPO was on 16/07/1991; the stock trades on NASDAQ under the ticker ALKS.
What do analysts say about Alkermes stock?
29 analysts rate the stock, the consensus is Buy (as of 22/09/2026).
The average price target is US$58.29, ranging from US$50.00 to US$65.00, with a median of US$56.00.
This is an external assessment, not a statement by Market Jury.
When does Alkermes report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 30% stronger than usual.
Does Alkermes pay a dividend?
No, Alkermes currently does not pay a dividend.
Which stocks are comparable to Alkermes?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Alkermes stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alkermes against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.